Optive Brand For Day And Night Dry Eye Management

Dry Eye Clinical Trial

Official title:

Optive Brand For Day And Night Dry Eye Management

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03208673
• Other study ID #: CMO-EAME-EYE-0485
• Status: Completed
• Phase: N/A
• Start date: July 3, 2017
• Est. completion date: September 6, 2017

Study information

• Verified date: March 2019
• Source: Allergan
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open label study of Optive eyedrops and gel combination for day and night dry eye management

Recruitment information / eligibility

• Status: Completed
• Enrollment: 35
• Est. completion date: September 6, 2017
• Est. primary completion date: September 6, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• OSDI score of = 23

• Ocular comfort at waking <65 on 100-point scale

• Conjunctival staining Grade = 2 (scale 0 to 4) in at least one eye

• Use of eyedrops for the relief of dry eye symptoms for at least one month

• Best corrected visual acuity in each eye of at least 20/25

• Have normal eyes with the exception of the need for visual correction; subjects must be willing to cease contact lens wear for the duration of the study

• Be willing and able to adhere to the instructions set in the clinical protocol and maintain the appointment schedule

Exclusion Criteria:

• Use of Benzalkonium Chloride (BAK) preserved eyedrops in the last month

• Use of Optive brand eyedrops in the last month

• Monocular participants (only one eye with functional vision).

• Contact lens wear during the study

• History of herpetic keratitis, ocular surgery or irregular cornea;

• Known pregnancy or lactation during the study period

• Participation in any clinical trial within 30 days of the enrollment visit

Related Conditions & MeSH terms

• Dry Eye
• Dry Eye Syndromes
• Keratoconjunctivitis Sicca

Intervention

Device:
• Optive® Fusion + Optive® Gel Drop
Optive® Fusion eyedrop will be used as needed up to four times a day but at least twice a day. The eyedrop will be used once in the evening; the gel drop being instilled any time during the last hour prior to sleep.

Locations

Country	Name	City	State
United Kingdom	Ocular Technology Group - international	London

Sponsors (1)

Lead Sponsor	Collaborator
Allergan

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in Ocular Surface Disease Index (OSDI) Total Score	A 12-question survey used to measure the symptoms of dry eye disease. Each of the 12 individual questions rate one symptom on a 0-4 scale, with 4 meaning that the symptom is present all of the time and 0 meaning the symptom is present none of the time. The overall ODSI score is calculated by adding all of the values from the 12 questions, multiplying that value by 25, and dividing the resulting value by the number of questions answered. This results in an overall scale that ranges from 0-100, with 100 being severe dry eye symptoms and 0 being no dry eye symptoms.	Change from baseline to (day 30 +/- 3 days)
Primary	Measured Lissamine Green Bulbar Conjunctival Staining (mm2)	The Lissamine Green (LG) bulbar conjunctival staining was analysed post-hoc for both eyes. The photos were masked and for each image the Staining Area was measured (mm2).	Change from baseline to (day 30 +/- 3 days)
Secondary	Change From Baseline in Visual Analogue Scale (VAS): Symptomatology Upon Waking	The participant rated the severity of their symptomatology upon waking using a VAS scale. Participants put a mark on a 100 millimeter line where 0 (far left on the line) = no symptoms to 100 (far right on the line) = most severe symptoms.	Baseline (day 0) to (day 30 +/- 3 days)